title: Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?
abstract: In acute lymphoblastic leukemia (ALL), the advent of methods to measure disease not detectable by morphology, ie, minimal residual disease (MRD), has set a new standard to define remission. The clinical importance of MRD has been demonstrated by numerous studies using either flow cytometry or polymerase chain reaction and involving thousands of patients. Results are in remarkable agreement on the association between MRD persistence and risk of subsequent relapse, regardless of the MRD detection method used. More recent data indicate that MRD can also be informative in specific subgroups of ALL patients, such as infants or those with T-lineage ALL. Hence, MRD is now being used in clinical trials to inform treatment decisions and guide patients' clinical management. This article reviews MRD methodologies and clinical applications with emphasis on recently reported technical advances and prognostic associations, and the practical issues related to the implementation of MRD monitoring in the clinic.
authors.affiliation: Department of Pediatrics, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. paedc@nus.edu.sg
authors.forename: Dario
authors.initials: D
authors.lastname: Campana
mesh_terms: D005434:Flow Cytometry; D006801:Humans; D018365:Neoplasm, Residual; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000175:diagnosis* / Q000473:pathology; D011379:Prognosis